Butterbur

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: inflammation pain immunity

Research Overview

Across the cited literature, butterbur (Petasites hybridus) has been studied primarily as a nutraceutical/phytomedicine for migraine prophylaxis, especially in patients with episodic migraine. It appears most often in clinical guideline and review contexts that synthesize randomized controlled trial (RCT) evidence alongside other complementary and integrative approaches (e.g., magnesium, riboflavin, coenzyme Q10, feverfew, and mind–body therapies). A secondary, distinct research area concerns safety and toxicology, particularly the presence of pyrrolizidine alkaloids (PAs)—mutagenic and carcinogenic plant toxins—either in butterbur preparations or in environmental contexts (e.g., contamination of water near PA-producing plants).

The strongest evidence summarized in these abstracts supports butterbur as an effective option for migraine prevention based on RCT-derived evidence incorporated into at least one evidence-graded prophylaxis guideline, where butterbur is listed among agents receiving a strong recommendation for use. Multiple narrative and integrative reviews similarly characterize butterbur as helpful/effective for migraine, while emphasizing that efficacy is contingent on preparation quality. In parallel, the strongest safety-related signal is that butterbur carries potential hepatotoxicity risk linked to PA content, and broader PA research underscores the persistence and health relevance of these compounds, reinforcing the rationale for minimizing exposure and for stringent control of PA contamination in medicinal products.

Key gaps include the need for newer, high-quality, independently replicated RCTs using standardized, well-characterized (including PA-free) butterbur extracts; clearer dose–response data; and longer-term follow-up to better define durability of benefit and rare adverse events. Additional research is needed to reconcile inconsistencies across guidelines and to strengthen comparative effectiveness evidence versus established pharmacologic preventives and other nutraceuticals. Finally, more rigorous work on product quality, regulation, and real-world safety surveillance—including verification of PA-free status and monitoring for hepatic outcomes—remains central to determining butterbur’s net clinical utility.

1. What conditions has Butterbur been studied for?

  • Migraine prevention (prophylaxis), especially episodic migraine: Multiple abstracts discuss butterbur as a prophylactic option and cite randomized, double-blind, placebo-controlled trials (notably with the butterbur root extract Petadolex®).

  • Tension-type headache: Mentioned as a therapeutic area where petasins (active constituents) may be beneficial, though the provided abstracts emphasize migraine more than tension headache.

  • Allergic rhinitis (and broader “rhinitis/sinusitis” alternative therapy literature): A rhinology Delphi/systematic review identified butterbur extract as having low to moderate-high GRADE-rated evidence in rhinitis/sinusitis literature, with allergic rhinitis being the most commonly studied condition.

  • Environmental/toxicology context (not a therapeutic indication): Pyrrolizidine alkaloids (PAs) associated with Petasites species were measured in water sources; this is about exposure risk rather than treatment.

2. Does it work in treating those conditions? Summarize the evidence.

  • Migraine prophylaxis: The guideline abstract reports butterbur among 11 agents receiving a strong recommendation for episodic migraine prophylaxis, with evidence drawn from randomized, double-blind, controlled trials and graded using established systems (USPSTF criteria; recommendations via GRADE).

    One mechanistic/clinical summary specifically states that in randomized, double-blinded, placebo-controlled trials with Petadolex®, migraine attack frequency was reduced significantly at 150 mg/day, and it reports no relevant abnormal liver function in those trials.

    Several review abstracts note that “older research” supports benefit of butterbur for migraine, while also emphasizing that newer complementary/integrative research has methodological limitations and that evidence strength varies across nutraceuticals.

  • Allergic rhinitis/sinusitis: The Delphi/systematic review concludes butterbur extract has a low to moderate-high GRADE rating among alternative therapies, and notes that most studies compare to placebo and that comparisons to standard therapies are lacking. This suggests potential efficacy, but with limitations in comparative effectiveness evidence.

  • Tension-type headache: The provided abstracts assert potential benefit of petasins for tension headaches, but do not provide specific trial outcomes in the text shown. Evidence in these abstracts is therefore less directly substantiated than for migraine.

3. What health benefits does it have?

  • Reduced migraine attack frequency (prevention): Clinical trial summaries in the abstracts report significant reduction in migraine attack frequency at 150 mg/day of Petadolex®.

  • Anti-inflammatory and anti-nociceptive mechanisms relevant to migraine biology: The mechanistic abstracts describe that butterbur/petasins:

    • Inhibit inflammatory mediator pathways by inhibiting cyclooxygenases, lipoxygenases, and phospholipase A2.

    • Desensitize pain signaling via effects on TRP ion channels (including TRPA1 and TRPV1).

    • Reduce CGRP (calcitonin gene-related peptide) release from trigeminal/meningeal afferents in experimental models—CGRP is described as a biomarker and promoting factor in migraine.

  • Potential benefit in allergic rhinitis: The rhinology evidence review suggests butterbur extract is among the more promising alternative therapies studied for rhinitis (most commonly allergic rhinitis), though details of magnitude of benefit are not provided in the abstract.

4. Does it have any downsides or side effects?

  • Hepatotoxicity concerns (product/preparation-dependent): One phytomedicine review explicitly states butterbur is effective with potential risks of hepatotoxicity related to preparation. Another guideline-focused nutraceutical review notes a “current controversy regarding butterbur and its safety.” These statements imply that safety depends heavily on how the product is manufactured and purified.

  • Pyrrolizidine alkaloids (PAs): A toxicology/environmental abstract highlights that PAs are persistent mutagenic and carcinogenic compounds produced by many plants and that Petasites hybridus is PA-producing. While this study measured PAs in water (not supplements), it reinforces the broader safety rationale for minimizing PA exposure and the importance of PA-free preparations.

  • Nonclinical safety signals at very high doses (animal data): A repeated-dose study summary reports a no-observable-adverse-effect level in rats at 15-fold the maximal clinical dose, but at 45–90-fold doses observed bile duct hyperplasia with mechanistic changes in solute carriers. This is not direct evidence of harm at typical human doses, but it is a signal at supratherapeutic exposure.

  • Limitations in the clinical safety evidence presented: The Petadolex® summary reports no relevant abnormal liver function in the cited RCTs and no hepatotoxicity in primary human hepatocytes at therapeutic levels (including with migraine co-medications), but abstracts do not provide full details on sample sizes, duration, rare adverse event detection, or post-marketing surveillance—so uncommon risks may be missed.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings for butterbur (e.g., differential efficacy or toxicity by genotype), and they do not identify specific gene–supplement interactions.

  • No direct evidence in these abstracts linking butterbur response to genetic variants (e.g., CGRP pathway genes, TRP channel genes, drug-metabolizing enzymes, or transporters).

  • Mechanistic relevance without genotype data: Because petasins are described as acting on TRPA1/TRPV1 signaling and reducing CGRP release, it is biologically plausible that genetic variation in these pathways could influence response, but this remains speculative based on the abstracts provided.

References

  1. Canadian Headache Society guideline for migraine prophylaxis.
    Tamara Pringsheim, W Jeptha Davenport, Gordon Mackie, Irene Worthington, Michel Aubé, Suzanne N Christie, Jonathan Gladstone, Werner J Becker (2012) - The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  2. Complementary and Integrative Medicine for Episodic Migraine: an Update of Evidence from the Last 3 Years.
    Rebecca Erwin Wells, Justin Beuthin, Laura Granetzke (2019) - Current pain and headache reports
  3. Nutraceuticals in migraine.
    Thilinie Rajapakse, Andreas R Gantenbein (2024) - Handbook of clinical neurology
  4. Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use.
    Thilinie Rajapakse, Tamara Pringsheim (2016) - Headache
  5. The invasive butterbur contaminates stream and seepage water in groundwater wells with toxic pyrrolizidine alkaloids.
    Vaidotas Kisielius, Jawameer R Hama, Natasa Skrbic, Hans Christian Bruun Hansen, Bjarne W Strobel, Lars Holm Rasmussen (2020) - Scientific reports
  6. Phytomedicines in the Treatment of Migraine.
    Thilinie Rajapakse, William Jeptha Davenport (2019) - CNS drugs
  7. Alternative headache treatments: nutraceuticals, behavioral and physical treatments.
    Christina Sun-Edelstein, Alexander Mauskop (2011) - Headache
  8. Alternative therapies for sinusitis and rhinitis: a systematic review utilizing a modified Delphi method.
    Arthur W Wu, John D Gettelfinger, Jonathan Y Ting, Claudia Mort, Thomas S Higgins (2020) - International forum of allergy & rhinology
  9. Hepatobiliary Events in Migraine Therapy with Herbs-The Case of Petadolex, A Petasites Hybridus Extract.
    Nora Anderson, Jürgen Borlak (2019) - Journal of clinical medicine
  10. Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review.
    Jürgen Borlak, Hans-Christoph Diener, Johanna Kleeberg-Hartmann, Karl Messlinger, Stephen Silberstein (2022) - Frontiers in neurology
  11. Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels.
    Johanna Kleeberg-Hartmann, Birgit Vogler, Karl Messlinger (2021) - The journal of headache and pain
  12. Petatewalide B, a novel compound from Petasites japonicus with anti-allergic activity.
    Young-Whan Choi, Kyoung-Pil Lee, Jung-Min Kim, Saeromi Kang, Soo-Jin Park, Jung-Min Lee, Hyung Ryong Moon, Jee H Jung, Young-Geun Lee, Dong-Soon Im (2016) - Journal of ethnopharmacology
  13. Oral toxicity study of certain plant extracts containing pyrrolizidine alkaloids.
    Oana Cristina Şeremet, Florica Bărbuceanu, Floriana Elvira Ionică, Denisa Marilena Margină, Claudia Maria GuŢu, Octavian Tudorel Olaru, Mihaela Ilie, Veaceslav Gonciar, Simona Negreş, Cornel ChiriŢă (2016) - Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  14. Impact of Food Components on in vitro Calcitonin Gene-Related Peptide Secretion-A Potential Mechanism for Dietary Influence on Migraine.
    Margaret Slavin, Julia Bourguignon, Kyle Jackson, Michael-Angelo Orciga (2016) - Nutrients
  15. Complementary and Integrative Approaches for Pediatric Headache.
    Sita Kedia (2016) - Seminars in pediatric neurology
  16. Simultaneous investigation of sesquiterpenes, pyrrolizidine alkaloids and N-oxides in Butterbur (Petasites hybridus) with an offline 2D-combination of HPLC-UV and LC-MMI-ToF-MS.
    Ahmet Alper Aydın, Thomas Letzel (2013) - Journal of pharmaceutical and biomedical analysis
  17. Aqueous extract of
    Eun Ji Kim, Jae In Jung, Young Eun Jeon, Hyun Sook Lee (2021) - Nutrition research and practice
  18. Antiproliferative effect of the methanol extract from the roots of
    Hyun Jung Kim, Song Yi Park, Hye Min Lee, Dong Ik Seo, Young-Min Kim (2015) - Experimental and therapeutic medicine
  19. Phytochemistry, Toxicology and Therapeutic Value ofPetasites hybridusSubsp. Ochroleucus (Common Butterbur) from the Balkans
    Tatjana Mihajilov-Krstev, Boris Jovanović, Bojan Zlatković, Jelena Matejić, Jelena Vitorović (2020)
  20. Therapeutic effects of s-petasin on disease models of asthma and peritonitis.
    Kyoung-Pil Lee, Saeromi Kang, Min-Soo Noh, Soo-Jin Park, Jung-Min Kim, Hae Young Chung, Nam Kyung Je, Young-Geun Lee, Young-Whan Choi, Dong-Soon Im (2015) - Biomolecules & therapeutics


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!